Neutrophils, a primary type of immune cell, play critical roles in numerous biological processes. Both umbilical cord blood (UCB) and peripheral blood are rich in neutrophils. UCB is more abundant than peripheral blood, with cells generally at a more immature stage. However, comparative data between these two cell sources is lacking. This study aims to elucidate differences between UCB-derived neutrophils (UCBN) and peripheral blood-derived neutrophils (PBN). UCBN and PBN were isolated from fresh human umbilical cord blood and peripheral blood, respectively. Transcriptomic profiling was performed and compared against neutrophil RNA from three different donors. Bioinformatics analysis was employed to compare cell phenotypes. A cytokine cocktail (IFN-β, IFN-γ, and LPS) was used to activate UCBN and PBN in vitro. A united multi-omic approach, combining transcriptomic and proteomic analysis, was followed by experimental validation through flow cytometry, cell killing assays, and proteome profiler array to verify cell functions. Transcriptomic analysis revealed that the most upregulated genes in freshly isolated umbilical cord blood neutrophils (UCBN) compared to peripheral blood neutrophils (PBN) predominantly involve neutrophil activation and cell-killing functions. Validation through flow cytometry and cell-killing experiments demonstrated that highly viable UCBN exhibited significantly stronger ovarian tumor cell-killing activity in vitro compared to PBN. Both transcriptomic and proteomic analyses indicated that the primary upregulated genes in activated UCBN are chiefly involved in biological processes related to the regulation of cytokine secretion. Integrative multi-omic analysis, including a proteome profiler array, confirmed that UCBN indeed secrete elevated levels of cytokines. In conclusion: UCBN shows higher viability and cellular activity compared with PBN, particularly in tumor cell-killing and cytokine secretion.
AJCR Copyright © 2024.

Lung CD8+ memory T cells play central roles in protective immunity to respiratory viruses, such as influenza A virus (IAV). Here, we find that alveolar macrophages (AMs) function as antigen-presenting cells that support the expansion of lung CD8+ memory T cells. Intranasal antigen administration to mice subcutaneously immunized with antigen results in a rapid expansion of antigen-specific CD8+ T cells in the lung, which is dependent on antigen cross-presentation by AMs. AMs highly express interleukin-18 (IL-18), which mediates subsequent formation of CD103+CD8+ resident memory T (TRM) cells in the lung. In a mouse model of IAV infection, AMs are required for expansion of virus-specific CD8+ T cells and CD103+CD8+ TRM cells and inhibiting virus replication in the lungs during secondary infection. These results suggest that AMs instruct a rapid expansion of antigen-specific CD8+ T cells in lung, which protect the host from respiratory virus infection.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

h4>Background: /h4> Neutrophils are a main type of immune cells involved in many important processes. During tumor progression neutrophils have manifested both tumor-promoting and inhibiting activities. Human umbilical cord blood (UCB)-derived Neutrophils (UCBN) were reported to have anti-tumor activity with ovarian cancer cell lines in vitro in our previous studies. However, the underlying mechanism remains unclear. This present study aims to uncover mechanisms underlying the inhibitory role of UCBN in ovarian cancer compared with peripheral blood-derived Neutrophils (PBN). h4>Methods: /h4>: UCBN and PBN were isolated from freshly obtained human umbilical cord blood and peripheral blood respectively. Cytokine cocktail (IFN-β, IFN-r, and LPS) were used to activate UCBN and PBN in vitro . Mechnism of activated UCBN anti-tumor were done by multi-omic: transcriptomic and Proteomics analysis, followed by experimental validation with flow cytometry, cell killing assays and proteome profiler array. h4>Results: /h4>: The transcriptomic analysis showed that the top upregulated genes in fresh isolated UCBN compared with PBN mainly focus on neutrophils activation and cell killing. High activity UCBN displayed strong ovarian tumor cell killing activity than PBN in vitro. Transcriptomic and proteomics analysis both revealed that the top upregulated molocules in activated UCBN were mainly involved in biologic processes related to regulation of cytokine secretion. United multi-omic analysis with proteome profiler array, we screened the anti-tumor molecule CCL3, which activated IFN-r related pathway JAK/STAT to killing tumor cells by RNA-seq. h4>Conclusions: /h4>: Hence UCBN may constitute a viable strategy for ovarian cancer immunotherapy.

Psoriasis is a chronic inflammatory skin disease that speeds up the life cycle of skin cells, forming scales and red patches that are itchy and sometimes painful. It is a complex disease of autoimmune origin and genetic predisposition with more than 10 different loci associated. Here we described the production of an iPSC line generated by Sendai Virus (Klf4, Oct3/4, Sox2 and c-Myc) reprogramming of Peripheral Blood Mononuclear Cells (PBMCs) from a Psoriasis patient. The iPSC line generated has normal 46XY karyotype, is free of SeV genome and transgenes insertions, express high levels of pluripotency markers and can differentiate into all three germ layers.
Copyright © 2020. Published by Elsevier B.V.

Autism spectrum disorders (ASDs) are a group of diseases that affect social interaction, communication and behavior. Molecular mechanisms involved in the pathogenesis of ASDs are complex due to genetic heterogeneity. Recently, pathogenic variants of SCN2A have been strongly associated with ASDs. Here, we generated iPSCs from a patient with ASD and a heterozygous nonsense mutation in SCN2A, by reprogramming mesenchymal stromal cells with non-integrating vectors. The generated iPSC line expresses pluripotency markers, presents a normal karyotype and is able to differentiate into the three germ layers. This iPSC line is a useful tool for modeling ASD and drug screening studies.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.